ASKA PHARMACEUTICAL HOLDINGS CO.,LTD. Press Release
Newsweek International Features ASKA Pharmaceutical
TOKYO, March 21, 2024 - ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886) is pleased to announce that Sohta Yamaguchi, President, Representative Director of its subsidiary, ASKA Pharmaceutical Co., Ltd. (hereinafter "ASKA"), was interviewed by the news agency, the Worldfolio PTE. LTD. and the article introducing ASKA was published in the US weekly magazine "Newsweek International." Please see the attached for the article content.
Reference:Newsweek International Features ASKA Pharmaceutical(aska-pharma-hd.co.jp)* announced on September 14, 2023
Newsweek is an American weekly magazine with a global readership of approximately 46 million people, and provides information on all areas of global culture, politics, economics, and social conditions. For the special feature "The Japanese Firms Accelerating Medical Innovation," Newsweek introduced ASKA as one of the firms in this issue.
The full interview is posted on the news website "The WORLDFOLIO."
https://www.theworldfolio.com/interviews/aska-we-create-new-value-as-leading-womens-healthcare-company/5872/
* The Worldfolio PTE. LTD. has granted permission to post the article here.
The Worldfolio PTE. LTD.：
The Worldfolio is a media agency and a news website that has been bringing high-quality content to readers around the globe for over 20 years. The Worldfolio PTE LTD is now based in Singapore and provides breaking news, in-depth analyses, and investigative stories about a wide range of topics and sectors, including manufacturing, real estate, construction, healthcare, digital transformation and more.
Media Contacts
ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp
The World's Best Hospitals
HOSPITAL
BOSSES ARE
BETTING ON
BIG TECH
1 5 . 0 3 . 2 0 2 4
ALBANIA €6.25 | DENMARK DKR57 | HONG KONG HK80 | LITHUANIA €8.99 | OMAN OR 3.250 | SINGAPORE $11.95 | UK £5.99 |
AUSTRALIA $11.00 | EGYPT E£ 65.00 | HUNGARY HUF 5.990 LUXEMBOURG €7.90 | POLAND PLN29.99 | SLOVAKIA €6.50 | US $10.99 | |
AUSTRIA €10.00 | FINLAND €7.60 | IRELAND €7.00 | MALTA €7.00 | PORTUGAL €7.00 | SOUTH AFRICA R55.00 | ZIMBABWE ZWD4.00 |
BAHRAIN BD4.25 | FRANCE €7.50 | ISRAEL NIS35 | MONTENEGRO €8.30 | QATAR QR65 | SPAIN €7.00 | |
BELGIUM €7.00 | GERMANY €7.50 | ITALY €7.00 | MOROCCO MDH70 | MALAYSIA RM27.90 | SWEDEN SKR119 | |
CHINA RM80 | GIBRALTAR £6.05 | KUWAIT KD3.00 | NEW ZEALAND $14.00 | ROMANIA LEI 42.00 | SWITZERLAND | |
CYPRUS €7.00 | GREECE €7.50 | LATVIA €6.50 | NIGERIA $3.40C | SAUDI ARABIA SR35.00 | CHF10.60 | |
CZECH REP CZK180 | HOLLAND €7.00 | LEBANON LL10,000 | NORWAY NKR119 | S LEONE SLL30,000 | UAE AED42 |
ASKA Pharmaceutical: Revolutionizing Women's Healthcare
In its drive to become a | |||||||||
women's healthcare pioneer, | "We aim to become | ||||||||
ASKA Pharmaceutical is | |||||||||
a total healthcare | |||||||||
committed to innovation and | |||||||||
company and a global | |||||||||
global expansion. | |||||||||
entity." | |||||||||
Sohta Yamaguchi, | Drugs for the treatment of thyroid | ||||||||
disease when launched in 1922 | |||||||||
President, | |||||||||
visions a future where ASKA | |||||||||
ASKA Pharmaceutical | |||||||||
expands globally, enriching lives | |||||||||
beyond Japan's borders. "By our | |||||||||
services, from prevention to post- | drugs and treatments but also | 105th anniversary in 2025, I | |||||||
treatment, meeting the evolving | medical equipment and related | hope to report our successful | |||||||
Head office in Tokyo | needs of a proactive populace. | services, offering comprehensive | achievements," he shares, hinting | ||||||
With innovative products like RE- | health services for females." | at forthcoming advancements in | |||||||
ASKA Pharmaceutical is today | LUMINA (relugolix) for uterine fi- | And in a world where self- | global expansion and new busi- | ||||||
the leading force in Japan's ob- | broids and endometriosis, and es- | medication is on the rise, ASKA | ness ventures. | ||||||
stetrics and gynecology sector, | sential products in | l sees opportuni- | In a nutshell, ASKA Pharma- | ||||||
showcasing a relentless pursuit of | of thyroid disea | obstacles. "Over- | ceutical isn't just about treating | ||||||
excellence in women's healthcare | Pharmaceutical | unter options are | ailments; it's about empowering | ||||||
that demonstrates its commit- | out by providing | ing popularity, | women, fostering health aware- | ||||||
ment beyond mere sales figures. | tive solutions. | this has led to | ness, and pioneering innovations | ||||||
"We aim to become a total health- | "We offer dr | growing health | that transcend borders. With Mr. | ||||||
care company and a global entity, | that provide tre | nsciousness of | Yamaguchi at the helm, the com- | ||||||
aligning with our corporate phi- | ment options | Japanese people | pany's journey towards global lead- | ||||||
losophy," says Sohta Yamaguchi, | women's health c | the revitalization | ership in women's health seems not | ||||||
the company's president. | lenges at every st | e healthcare mar- | just promising but inevitable. | ||||||
ASKA's strategic shift to a hold- | life," Mr. Yamag | he adds. | |||||||
ings model enables the company | explains. "We | Three core areas with a | Looking forward, | ||||||
to offer comprehensive health | to not only provide | focus on pharmaceuticals | Mr. Yamaguchi en- | www.aska-pharma.co.jp |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
ASKA Pharmaceutical Co. Ltd. published this content on 21 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 March 2024 02:36:01 UTC.
